Bimekizumab Outperforms IL-17 Inhibitors in Real-World Psoriasis Study
KEY TAKEAWAYS
Bimekizumab demonstrated faster and more robust PASI improvements compared to secukinumab and ixekizumab in a recent real-world study.
Exponential modeling showed a steeper early response trajectory with bimekizumab, particularly among patients previously treated with IL-23 inhibitors.
All three IL-17 inhibitors showed favorable safety profiles, with no serious adverse events reported during the 12-week study period.
Bimekizumab demonstrated a faster and more robust response than secukinumab and ixekizumab in a real-world cohort of Polish patients with moderate-to-severe plaque psoriasis.
Researchers conducted a retrospective analysis from 2019 to 2024 that included 98 patients evaluated after initiating treatment with one of the three IL-17-targeting biologics. Inclusion criteria included PASI ≥ 10, BSA ≥ 10, DLQI ≥ 10, or psoriasis in special areas inadequately controlled by or contraindicated for at least two systemic therapies. Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI) scores were measured at baseline, week 4, and week 12. Patients previously exposed to IL-17 inhibitors were excluded from the analysis.
After adjustment for dosing interval differences, bimekizumab achieved the largest effect size in PASI reduction (Hedges’ g = 3.662), beating secukinumab (2.813) and ixekizumab (1.986). The steeper early response trajectory (intercept = 0.289) suggested a rapid clinical onset. Bimekizumab was especially effective among patients previously on IL-23 inhibitors. All three agents had favorable safety and tolerability profiles.
“This real-world analysis confirmed that IL-17 inhibitors effectively improved PASI, BSA, and DLQI scores in moderate-to-severe psoriasis,” the authors wrote. “Bimekizumab demonstrated the most rapid early improvements and a higher modeled likelihood of complete clearance, without significant differences at week 12. All agents were well tolerated, underscoring the need for further individualized, large-scale studies.”
Source: Kruczek W, et al. Journal of Clinical Medicine. 2025; 14(15):5421. https://doi.org/10.3390/jcm14155421